June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Predictors of Failure with Transscleral Diode Laser Cyclophotocoagulation in the Treatment of Refractory Glaucoma
Author Affiliations & Notes
  • Samantha Dewundara
    Department of Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Bret Hughes
    Department of Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Rominder Momi
    Department of Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Justin Tannir
    Department of Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Chaesik Kim
    Department of Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Footnotes
    Commercial Relationships Samantha Dewundara, None; Bret Hughes, None; Rominder Momi, None; Justin Tannir, None; Chaesik Kim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1858. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Samantha Dewundara, Bret Hughes, Rominder Momi, Justin Tannir, Chaesik Kim; Predictors of Failure with Transscleral Diode Laser Cyclophotocoagulation in the Treatment of Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1858.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: This study was conducted to evaluate prognostic indicators for failure with transscleral diode laser cyclophotocoagulation (TSDLCP) in the treatment of refractory glaucoma

Methods: This retrospective study analyzed 100 eyes in 100 patients with glaucoma refractory to conventional medical and/or surgical management and subsequently treated with TSDLCP. Failure in treatment was defined as intraocular pressure (IOP) measured < 5 or >22 mmHg, increase in number of antiglaucoma medications and need for additional diode or incisional surgery. Prognostic variables analyzed include patient age, sex, race, diagnosis of diabetes, diagnosis or hypertension, type of glaucoma, number of pre-laser IOP lowering medications used and pre-laser IOP. Data were analyzed using Cox regression and Kaplan-Meier Survival analysis.

Results: Mean patient age was 63±17 years (range 24-89 years). Fifty males and fifty females were studied. With respect to race, 71 African-Americans, 19 Caucasians and 10 other races were studied. Patients had chronic open-angle glaucoma (n=43), chronic angle-closure glaucoma (n=25), neovascular glaucoma (n=22) and other forms of glaucoma (n=10). Forty patients were diagnosed with diabetes mellitus and 72 with hypertension. Average pre-laser IOP was 37 ±12 mmHg. Mean follow up was 12 ± 10 months. Patients received 20 ± 6 laser applications per session, each application lasting 2 seconds in duration, ranging from 180-360 degrees. Total laser energy delivered per eye was 38 ±14 Watts. A success of 45% was noted at mean follow up of 12 months using Kaplan -Meier survival analysis, with a mean post-treatment IOP of 22 ±12mmHg at 12 months (P<0.05). Age, sex, race, diabetes, hypertension, type of glaucoma, number of pre-laser IOP lowering medications used and pre-laser IOP were not prognostic indicators of treatment failure (COX regression analysis, P>0.05).

Conclusions: With significant reductions in IOP, TSDLCP is a safe and effective alternate treatment for refractory glaucoma. Age, sex, race, diabetes, hypertension, type of glaucoma, number of pre-laser IOP lowering medications used and pre-laser IOP do not appear to impact success of treatment.

Keywords: 578 laser • 455 ciliary body  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×